Santhera Announces Successful Completion of First Clinical Trial with Omigapil in Patients with Cong
Updated: Feb 18
Please see the end of this article for
Frequently Asked Questions - CALLISTO Phase 1 Clinical Trial
Pratteln, Switzerland, April 5, 2018 - Santhera Pharmaceuticals (SIX: SANN) reports the successful completion of the first clinical trial with omigapil in patients with two forms of congenital muscular dystrophy (CMD) conducted in the US at the National Institutes of Health (NIH). The ascending multiple dose cohort study (CALLISTO) met its primary objective to establish a favorable pharmacokinetic profile of omigapil and demonstrated that the study drug was safe and well tolerated in children and adolescents with CMD. Following further data analysis, the Company will discuss these results with clinical experts and regulatory authorities to prepare for a pivotal trial in patients with CMD.
The single-center interventional trial to establish the pharmacokinetic profile and to evaluate the safety and tolerability of omigapil in pediatric and adolescent patients with CMD was conducted at the NIH's clinical center in Bethesda, Maryland (USA), and led by Carsten Bönnemann, MD, and A. Reghan Foley, MD, of the NIH's National Institute of Neurological Disorders and Stroke. Ambulant and non-ambulant patients aged 5-16 years with either of two of the most common forms of CMD resulting from collagen VI-deficiency (COL6-related dystrophies or COL6-RDs) or laminin alpha2-deficiency (LAMA2-related dystrophy or LAMA-RD) were eligible to participate in the trial. A total of 20 patients were enrolled in this ascending multiple dose cohort study. Participants were randomized to one of five groups and received omigapil at a once-daily dose ranging from 0.02 mg/kg to 0.08 mg/kg body weight as a liquid oral formulation for a period of 3 months.
The trial met its primary objective and established that the pharmacokinetic profile of omigapil is suitable for further development in pediatric patients and demonstrated that omigapil was safe and well tolerated in this fragile population of CMD patients.
"We are grateful to participating patients and their families for enrolling in this first interventional trial with a drug candidate for CMD and to the clinical researchers at the NIH for their dedication to this milestone trial for these forms of CMD," said Thomas Meier, PhD, CEO of Santhera. "This is an important step towards profiling the therapeutic potential of omigapil for the LAMA2 and COL6 related forms of CMD for which there is currently no treatment available. We will now collaborate with international experts and seek advice from regulators to further advance the clinical development of omigapil towards a pivotal trial."
"This collaboration with Santhera and the patient community allowed us to test for the first time an investigational therapy in children with these more common types of CMD for which no other treatment options are currently available," said Carsten Bönnemann. "With the help of Ken Cheung, PhD at Columbia University, this clinical trial applied an innovative design by utilizing a novel adaptive dose-finding algorithm. Upon full analysis, we will share detailed data from the CALLISTO trial at upcoming scientific conferences and with the patient community. We look forward to continue working with Santhera, all stakeholders and regulators to define the fastest development path towards pivotal efficacy studies for this drug candidate."
"Cure CMD and the CMD community are thrilled that this first-ever interventional trial for congenital muscular dystrophy has been successfully completed, in partnership with the NIH and Santhera Pharmaceuticals," added Rachel Alvarez, Director of Operations for Cure CMD, a leading non-profit organization focused on finding treatments and supporting the CMD community. "For the affected individuals and their families who enrolled in CALLISTO, trial participation represented a considerable burden, and we are forever grateful for their commitment to seeing this through to the end."
About Omigapil and the CALLISTO study Omigapil is a deprenyl-analog with anti-apoptotic properties. Santhera obtained an exclusive license for omigapil from Novartis for the development in congenital muscular dystrophies (CMDs). Nonclinical studies in a disease-relevant model showed that omigapil inhibits cell death and reduces body weight loss and skeletal deformation, while increasing locomotive activity and protecting from early mortality (Erb M et al., J Pharmacol Exp Ther 2009, 331:787-795). Omigapil has orphan drug designations for CMD in the US and Europe and was granted Fast Track Designation by the FDA.
The preparation and conduct of the Phase I CALLISTO trial was supported financially by a public-private partnership including two patient organizations, the US-based Cure CMD and the Swiss Foundation for Research on Muscle Diseases (FRSMM), EndoStem, an EU 7th Framework program, and NIH clinical resources. In addition, the CALLISTO study was supported by an award from the Office of Orphan Products Development (OOPD) at the US Food and Drug Administration (FDA). About Congenital Muscular Dystrophy Congenital muscular dystrophies (CMDs) are inherited neuromuscular conditions characterized by congenital-onset weakness and hypotonia and have associated dystrophic findings on muscle biopsy. Progressive muscle weakness, joint contractures and respiratory insufficiency characterize most CMDs. LAMA2-related and COL6-related dystrophies are the most common forms of CMD for which no pharmacological therapy is currently available or in advanced clinical development. About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for orphan and other diseases with high unmet medical needs. The portfolio comprises clinical stage and marketed treatments for neuro-ophthalmologic, neuromuscular and pulmonary diseases. The most advanced pipeline product, idebenone, is in clinical Phase III for the treatment of Duchenne muscular dystrophy (DMD). Santhera's Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and currently commercialized in 20 countries. For further information, please visitwww.santhera.com.
Raxone® is a trademark of Santhera Pharmaceuticals. For further information please contact: email@example.com or
Eva Kalias, Head External Communications
Phone: +41 78 671 98 86 firstname.lastname@example.org For Investors: email@example.com or Christoph Rentsch, Chief Financial Officer Hans Vitzthum, LifeSci Advisors Europe: +41 61 906 89 65 US: +1 212 915 2568 firstname.lastname@example.org email@example.com
Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
Frequently Asked Questions – CALLISTO Phase 1 Clinical Trial
What is CALLISTO? CALLISTO is a phase 1, ascending multiple dose cohort trial to establish the pharmacokinetic profile of omigapil in paediatric and adolescent patients with CMD and to evaluate the safety and tolerability of omigapil.
Who funded the trial? The study sponsor is Santhera Pharmaceuticals. Significant additional funding was provided by Cure CMD; the Swiss Foundation for Research on Muscle Diseases (FRSMM); EndoStem, an EU 7th Framework program; and, a FDA Orphan Products Development grant. Moreover, the NIH contributed significantly by conducting this study.
What is omigapil? Omigapil is a small molecule, an oral drug, which was first discovered and clinically developed by Novartis. Santhera licensed omigapil to study for development in congenital muscular dystrophy.
How does omigapil work? Omigapil’s proposed mechanism of action is anti-apoptosis, meaning it prevents cell death. Studies in a mouse model of the MDC1A type of congenital muscular dystrophy have shown that omigapil inhibits cell death and reduces body weight loss and skeletal deformation, while increasing locomotive activity and protecting from early mortality. There is some data suggesting this is the case in Collagen VI CMD as well.
Will omigapil only being further developed in the Collagen VI- and MDC1A-subforms of CMD?
Collagen VI and MDC1A subforms of congenital muscular dystrophy have the strongest evidence to support that apoptosis (or programmed cell death) occurs in the disease and that a drug with anti-apoptotic properties could help treat the disease.
How is omigapil delivered? The omigapil drug substance is a white, micronized powder. For clinical administration, it is used as a liquid formulation orally. The liquid form of omigapil offers flexible dosing, and can be tolerated by patients with swallowing difficulties or used in g-tubes.
What is a Phase 1 trial? A phase 1 trial is a smaller trial, typically enrolling 20-100 healthy volunteers or people with the disease with the purpose of studying pharmacokinetics and safety/tolerability. Phase 1 studies are closely monitored and gather information about what the body does with the drug (absorption, distribution, metabolism, excretion), how much of a drug the body can tolerate and what the side effects of a drug are. Early information about how to best administer the drug to limit risks and maximize possible benefits also can be obtained. Omigapil had already been investigated previously in healthy volunteers but additional information needed to be gathered in children and adolescents, using a liquid formulation, and in the CMD patient population. The study protocol of the CALLISTO trial had been reviewed and was agreed with the US FDA. What does pharmacokinetic mean? A pharmacokinetic study examines how a drug moves through the body. The time it takes for a drug to be absorbed, distributed, metabolized, and excreted is studied and amounts of active and metabolized drug are quantified. This type of study is necessary to develop safe and effective therapies and identify a suitable formulation and dose. We had to conduct this study because it was not known how this formulation acted in the body of children and adolescent with CMD. Omigapil was previously studied using tablets in an adult population.
Why was there only one study site (in the U.S.)? The NIH under the leadership of Dr. Bönnemann and Dr. Foley and their team was well-positioned to undertake the first investigative drug trial in this disease. Further clinical studies will be conducted in several countries in Europe and the US.
Who was eligible to participate in this study and how were patients chosen? Ambulatory and non-ambulatory children ages 5-16 years with clinical picture consistent with collagen VI-deficient (Ullrich) or laminin alpha-2 (merosin) deficient (MDC1A) CMD were eligible to participate in the trial. Participants were on stable doses of any allowed concomitant medications for one month prior to dosing.
Recurrent hospitalisation for chest infections in previous 2 years
Patients with respiratory function parameters (eg: low pulmonary function test value) currently affected by short term medications, or acute illness/ conditions
Any need for surgery (scoliosis, gastrostomy, other) 6 months prior to the study or planned during the course of the study
Weight less than 17kg at Baseline
Morbidly obese or grossly overweight
History of epilepsy or on antiepileptic medication at Screening/Baseline
On daytime non-invasive Ventilation (NIV)
Anticipated need for anesthesia during the course of this study
Patients with renal impairment or with moderate to severe hepatic impairment
Cure CMD, MDA and the NIH advertised the trial and Cure CMD reached out specifically to patients who might qualify.
Did the trial participants experience any notable gains in strength? Because this is a phase 1 trial focused on dosing and safety, we don’t anticipate seeing any changes in the strength of patients over the three months they were on omigapil. The number of patients and the duration of the trial was too small to expect any measurable clinical effect. However, we will continue to analyse the data from the study and share those with the CMD community.
Will omigapil make my child stronger? We hope to examine the efficacy of omigapil in a future trial, but this trial was focused on safety, pharmacokinetic profile and dosing. We have no data yet on the efficacy of omigapil.
Will omigapil cure CMD?
No, we do not anticipate omigapil to be a complete “cure” as most people think of it. We do hope that omigapil will be shown to positively impact the symptoms, muscle weakness, muscle breakdown and mortality associated with CMD, but future studies are needed to determine that.
Are there any harmful effects from taking omigapil? There were no safety concerns during the trial. The Drug Safety Monitoring Board concluded that omigapil was safe and well tolerated in the paediatric and adolescent population of CMD patients enrolled in CALLISTO.
How long did the trial take to conduct? As this was a trial requiring a step-wise change of the dose and included very intense monitoring of the patients, it took almost two and a half years to complete. The first patient was dosed in July of 2015 and the last visit of the last patient in the trial was in January of 2018.
When will the full results be released?
We will be taking the next months to fully analyse the trial data. The investigators of the NIH will release the findings at upcoming scientific meetings. At that time, we will hold a webinar for the CMD community to share these results and answer questions.
Now that the trial is over, does it mean that omigapil is now available for me/my child to take? Omigapil is still an investigational drug and is not available by prescription. There are studies that still need to take place in addition to discussions with the regulatory authorities prior to omigapil being approved.
What is a phase 2 trial?
A phase 2 trial traditionally follows a phase 1 trial. The drug would be administered to a larger number of patients with the goal of studying efficacy (benefits) and side effects of the drug. In rare diseases such as CMD, a phase 2 trial could be suitable as pivotal trial supporting an approval. We will discuss this option with regulators in the US and Europe.
Are there plans for a Phase 2 trial? What conditions must be met before this can be decided? Prior to planning a phase 2 trial, we must fully analyse the results of the phase 1 study, determine that we have reliable endpoints for a future trial, and talk with regulators about the best development path to approval.
We also will assemble a scientific advisory group of leading experts in the CMD field to discuss how to best move forward with the development of omigapil for CMD.
When will these advisors meet? We plan to have such a first meeting during summer 2018.
Will there be multiple sites in a Phase 2 trial? Yes, in the case of a phase 2 trial we would have multiple study sites.
How do we volunteer to participate in a Phase 2 trial? We aren’t at that point yet. The best thing families can do is make sure their information is entered and up-to-date in the Cure CMD-sponsored Congenital Muscle Disease International Registry (CMDIR). The CMDIR proved a vital resource for us to fully recruit this study.
What can we do to ensure a Phase 2 trial happens (advocacy, fundraising, etc.)? We are working with experts and advocacy groups to move omigapil forward in the most expeditious way possible.
When will you know what the next steps are and the timeline to start the next trial? We will be able to better inform the community about the next steps and our timeline near the end of 2018.
How long will it be until omigapil comes to market and is available to patients? There are additional trials to take place before then and it is premature to speculate on timelines at this point.
How much will omigapil cost? There is a significant amount of work that needs to take place before thinking about the price of a drug. We need to establish the efficacy of the drug, conduct additional trials, meet with advisors, and meet with regulatory authorities. At this stage we have no guidance on future pricing.
What is an orphan drug? Omigapil has orphan drug designation in the United States and Europe. This is awarded to investigational drug candidates aimed to treat rare diseases.
What is Fast Track Designation? Omigapil has Fast Track Designation in the United States from the FDA. Fast track is a process designed to expedite the development and review of drugs to treat a serious condition and fill an unmet medical need.
Fast Track Designation affords the company developing the drug more frequent communication from the FDA, eligibility for an Accelerated Approval and Priority Review if certain criteria are met, and a rolling review (completing sections of the application and submitting them for review rather than wait until the entire application is completed for the review to begin).
Who can I contact for additional information? Please contact Santhera’s Head of Patient Advocacy for the U.S., Jodi Wolff, at Jodi.firstname.lastname@example.org or the Head of Patient Advocacy for Europe, Vanessa dos Reis Ferreira at email@example.com . We are happy to answer any questions that you have about the trial and next steps.